Introduction
Neonatal mass screening for congenital adrenal hyperplasia (CAH) has been performed in Japan since 1989. Steroid 21-hydroxylase deficiency (21-OHD) represents about 95% of CAH patients and is traditionally divided into three forms, severe classical salt-wasting (SW), simple virilizing (SV) and the milder non-classical (NC) form. Very rare cases of the NC form have been detected because of elevated 17-hydroxyprogesterone (17-OHP) levels at neonatal mass screening in Japan (1). The estimated rate of detection of the NC form by mass screening seems to be low (1:1,100,000) (1). This disease is caused by deletions or mutations of CYP21A2. In Japan, the P30L mutation appears more likely to be associated with Japanese NC patients (1). Here, we report a rare H62L mutation with the NC form in a Japanese 21-OHD patient.
Case Report
The patient was a female who was the second child of non-consanguineous parents and was born at 40 wk gestation with a body weight of 3,408 g after an uncomplicated pregnancy. High levels of 17-OHP were detected by neonatal screening for 21-OHD, and she was referred to our department at 27 d of age. Her 17-OHP level in dried blood was 15.21 ng/ml (cut off limit: 10 ng/ml) without initial steroid extraction from the filter paper sample at 5 d of age and 7.8 ng/ ml (cut off limit: 2 ng/ml) with steroid extraction at 20 d of age. She did not show any signs of 21-OHD, such as skin pigmentation, poor weight gain, vomiting or virilization of external genitalia except that her clitoral size was at the upper limit for normal (6 mm length, 5 mm width). Her serum 17-OHP level was continuously elevated (74 ng/ml at 27 d of age and 110 ng/ml at 45 d, respectively). Serum Na, K and plasma renin activity were normal (139 mEq/l, 5.9 mEq/l and 4.9 ng/ml/h, respectively). Her plasma ACTH (204 pg/ml) and serum androstendione (2.9 ng/ Vol.18 / No.4 ml; reference range 0.15-1.5) levels were elevated. Based on the persistent elevations of serum 17-OHP, ACTH and androstendione, the patient was diagnosed as having the NC form of 21-OHD. After obtaining informed consent, direct sequencing was performed for CYP21A2 using leukocyte genomic DNA from this patient and her parents in accordance with previously reported methods (2) . DNA analysis demonstrated an H62L mutation in exon 1 derived from her father and E6 cluster mutations (I236M, V237E, M239K) from her mother (Fig. 1) .
Discussion
We identified the first Japanese patient with the NC form of 21-OHD, and this patient had a rare H62L mutation of CYP21A2. So far, mutation of H62L has been described in only 16 other ethnic patients in the NC or SV form of 21-OHD (3, 4) . In most of these patients, H62L has been associated on the same allele with another mild mutation, such as P30L or P453S (H62L+P30L or H62L+P453S), and only two patients with the NC form have had an isolated H62L mutation. The genotype of these two patients was a combination of H62L and gene deletion or I172N. Functional analysis revealed that the residual enzymatic activity of H62L showed values of 20 to 60% as well as that of P453S or V281L, which are responsible for the NC form (3, 4) . On the other hand, the E6 cluster is classified as a null mutation. These data indicated that the combination of H62L in one allele and deletion/mutations on the other allele is related to the NC form. Therefore, the phenotype of our patient is in agreement with the genotype of the combination of H62L and E6 cluster mutations. However, it is of note that our patient's basal 17-OHP level was plotted between the SV and NC forms in the nomogram reported by Wilson RC et al. (5) . As mentioned, H62L mutation is often associated on the same allele with a mild mutation; however, our sequence analysis did not find any other mutation than H62L in the allele from the father. Thus, the exact reason of this discrepancy between the phenotype and 17-OHP level is unknown. Further accumulation of data for Japanese 21-OHD patients carrying the H62L mutation is needed to clarify this point.
In conclusion, we reported a rare H62L mutation of CYP21A2 in a patient with the NC form 21-OHD.
